Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of June 19, 2025 • 5:00 AM ET

Date/Time Source News Release
06/02/2025 07:00 AM EDT GlobeNewswire Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS)
05/07/2025 07:00 AM EDT GlobeNewswire Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025
05/06/2025 04:01 PM EDT GlobeNewswire Lyra Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
03/13/2025 04:01 PM EDT GlobeNewswire Lyra Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
11/12/2024 04:01 PM EST GlobeNewswire Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
10/15/2024 07:00 AM EDT GlobeNewswire Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis
09/27/2024 07:00 AM EDT GlobeNewswire Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings
08/14/2024 04:01 PM EDT GlobeNewswire Lyra Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
05/21/2024 09:14 AM EDT GlobeNewswire Lyra Therapeutics Announces Cost-Cutting Measures to Preserve Capital
05/06/2024 07:59 AM EDT GlobeNewswire Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis
Page

Additional News

As of June 19, 2025 • 5:00 AM ET

Date/Time Source News Release
06/16/2025 04:14 PM EDT SeekingAlpha Lyra Therapeutics: Regulatory Pathway For Non-Polyp Patients, An Underappreciated Catalyst
06/12/2025 12:00 PM EDT Zacks Lyra Therapeutics (LYRA) Upgraded to Buy: Here's Why
06/05/2025 12:55 PM EDT Zacks Lyra Stock Soars 356% in a Week on Strong Rhinosinusitis Study Success
06/03/2025 10:47 AM EDT IBN Spotlights Lyra Therapeutics Inc. (NASDAQ: LYRA) Rises Sharply in 6/3 Early Trading Session
06/02/2025 03:46 PM EDT SeekingAlpha Microcap Lyra Therapeutics surges 376% on phase 3 rhinosinusitis data
06/02/2025 10:29 AM EDT IBN Spotlights Lyra Therapeutics Inc. (NASDAQ: LYRA) Rises Sharply in 6/2 Early Trading Session
06/02/2025 09:04 AM EDT 24/7 Market News Siyata Mobile's $160M Core Gaming Merger Closing Date Nears Without Advance Notice
05/06/2025 05:20 PM EDT Zacks Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Lags Revenue Estimates
05/06/2025 05:13 PM EDT SeekingAlpha Lyra Therapeutics GAAP EPS of -$0.13 beats by $0.01, revenue of $0.18M beats by $0.02M
05/06/2025 07:00 AM EDT US Earnings Reports Expected US Company Earnings on Tuesday, May 6th, 2025
Page

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.